← All trials
NCT07246187
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 6, 2025
- Primary completion
- Oct 31, 2026
- Completion date
- Nov 30, 2026
- First posted
- Nov 24, 2025
- Last posted
- Nov 24, 2025
- Enrollment
- 114
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Mercy Bon Secours Saint Vincent Medical CenterLead sponsor
- Mercy Bon Secours Saint Vincent Medical CenterSponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.